213 related articles for article (PubMed ID: 27678456)
1. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
[No Abstract] [Full Text] [Related]
2. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin.
Fan D; Yang H; Mao W; Rask PJ; Pang L; Xu C; Vankayalapat H; Ahmed AA; Bast RC; Lu Z
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503955
[TBL] [Abstract][Full Text] [Related]
3. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
[TBL] [Abstract][Full Text] [Related]
4. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer.
Wang F; Yu X; Qian J; Cao Y; Dong S; Zhan S; Lu Z; Bast RC; Song Q; Chen Y; Zhang Y; Zhou J
Drug Resist Updat; 2024 May; 74():101077. PubMed ID: 38518726
[TBL] [Abstract][Full Text] [Related]
5. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
6. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
Zhang S; Lu Z; Mao W; Ahmed AA; Yang H; Zhou J; Jennings N; Rodriguez-Aguayo C; Lopez-Berestein G; Miranda R; Qiao W; Baladandayuthapani V; Li Z; Sood AK; Liu J; Le XF; Bast RC
PLoS One; 2015; 10(7):e0131833. PubMed ID: 26146988
[TBL] [Abstract][Full Text] [Related]
7. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells.
Raab M; Rak M; Tesch R; Gasimli K; Becker S; Knapp S; Strebhardt K; Sanhaji M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359562
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
Wei S; Qi L; Wang L
Anticancer Drugs; 2021 Jun; 32(5):496-507. PubMed ID: 33735118
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
10. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
11. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
[TBL] [Abstract][Full Text] [Related]
12. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
14. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
15. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
16. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways.
Jia L; Jin H; Zhou J; Chen L; Lu Y; Ming Y; Yu Y
BMC Complement Altern Med; 2013 Feb; 13():33. PubMed ID: 23410205
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
[TBL] [Abstract][Full Text] [Related]
18. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
[TBL] [Abstract][Full Text] [Related]
19. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
Mills KA; Roach ST; Quinn JM; Guo L; Beck HM; Lomonosova E; Ilivicky AR; Starks CM; Lawrence JA; Hagemann AR; McCourt C; Thaker PH; Powell MA; Mutch DG; Fuh KC
Gynecol Oncol; 2018 Nov; 151(2):337-344. PubMed ID: 30190114
[TBL] [Abstract][Full Text] [Related]
20. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]